Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of the included studies

From: Disease severity, debridement approach and timing of drug modify outcomes of adjunctive azithromycin in non-surgical management of chronic periodontitis: a multivariate meta-analysis

Author/Year n/ Country n (Female/Male) Age (years) Project Design Intervention Methodology Nature of S/RSD Intervention Groups Follow-Up Periodontal Maintenance Adverse Events
Mascarenhas et al. 2005 [28] 30/ USA AZI: 15 (4/11)
C: 15 (7/8)
AZI: 47.0 ± 10.1
C: 45.3 ± 10.8
Parallel, Single Blinded AZI: Post therapy, End of S/RSD, in 2 sessions within 14 days
C: S/RSD in 2 sessions within 14 days.
Qu S/RSD(2 sessions) AZI: 500 g × 1 day + 250 g × 4 days
C: S/RSD
3, 6 months from baseline 3rd, 6th months by examiner Not reported
Gomi et al. 2007 [25] 34/ Japan AZI: 17 (9/8)
C: 17 (9/8)
AZI: 45.4 ± 14.3,
C: 51.0 ± 8.8,
not described AZI: Pre-therapy, 3 days prior to S/RSD
C: S/RSD in 4–6 times, weekly intervals
FMD AZI: 500 g × 3 days
C: S/RSD
1, 3, 6 months from baseline Weekly by Dental Hygienist Diarrhoea (n = 1)
Haffajee et al. 2007 [32] 48/ USA AZI: 25 (10/15),
C: 23 (7/16)
AZI:47 ± 14,
C:43 ± 15
Parallel. Single Blinded AZI: Pretherapy,
Start of Quadrant Wise S/RSD
C: S/RSD in 4 weekly intervals
Qu S/RSD (4 sessions) AZI: 500 g × 3 days
C: S/RSD
1, 3, 6, 12 months from baseline 1st, 3rd, 6th and 12th months Difficulty in swallowing (n = 1)
Allergic reaction (n = 1)
Yashima et al. 2009 [27] 30/ Japan AZI 1: 10 (6/4),
AZI 2: 10 (5/5),
C: 10 (4/6)
AZI 1: 51.1 ± 11.6,
AZI 2: 50.8 ± 14.2,
C: 51.0 ± 10.6
not described AZI 1: Pre therapy
3 days prior to S/RSD (Full Mouth)
AZI 2: Pre therapy
3 days prior to S/RSD. Conducted in 3 times, within 7 days
C: S/RSD in 6 sessions with 1 week interval
FMD
Qu S/RSD (3 sessions)
AZI 1: 500 g × 3 days
AZI 2: 500 g × 3 days
C: S/RSD
1, 3, 6, 9, 12 months from baseline Once a month by the Dental Hygienist Diarrhoea (n = 1)
Oteo et al. 2010 [30] 28/ Spain AZI: 15 (8/7), C: 13 (5/8) AZM: 46.6,
C: 7.1
Parallel, Double Blind, Placebo Controlled. AZI: Post therapy,
End of S/RSD in 2 times, within 7 days
C: S/RSD in 2 times, within 7 days.
Qu S/RSD –(2 sessions) AZI: 500 g × 3 days
C: Placebo ×  3 days
1, 3, 6 months from baseline 1st, 3rd, 6th months Diarrhoea n = 1)
Sampaio et al. 2011 [34] 40/ Brazil AZI: 20 (7/13), C: 20 (9/11) AZI: 44.4 ± 7.42,
C: 43.5 ± 5.90
Parallel, Double Blind, Placebo Controlled AZI: Post therapy,
End of S/RSD in 4–6 times, within 14 days
C: S/RSD in 4–6 sessions within 14 days
Qu S/RSD (4–6 sessions) AZI: 500 g × 5 days
C: Placebo ×  3 days
6, 12 months from baseline Not reported Diarrhoea (n = 1); Excessive Sleepiness (n = 3)
Headache (n = 1)
Han et al. 2012 [33] 28/ Turkey AZI: 14 (4/10), C: 14 (6/8) AZI: 46.8 ± 5.1
C: 44.8 ± 5.0
Parallel, Double Blind, Placebo Controlled AZI: Post therapy,
End of quadrant by quadrant S/RSD in 4 sessions
C: Quadrant by quadrant S/RSD in 4 sessions
Qu S/RSD (4 sessions) AZI: 500 g × 3 days
C: Placebo ×  3 days
1, 3, 6 months from baseline Not Reported None
Fonseca et al. 2015 [29] 85/ Brazil AZI 1: 15, C 1: 15
AZI 2: 14, C 2: 13
44.6 ± 8.8 Parallel, double blinded AZI 1: Pretherapy, Start of full mouth S/RSD.
C 1: Full mouth S/RSD within 24 h in 2 sessions.
AZI 2: Pretherapy, Start of quadrant S/RSD.
C 2: S/RSD per quadrant for 30 min in weekly interval between sessions
1. FMD (2 sessions in 24 h)
2. Qu S/RSD (4 weekly sessions)
AZI:
500 g × 3 days
C: S/RSD alone
3, 6 months from baseline Not reported None
Martande et al. 2016 [31] 70/ India AZI: 35 (14/21), C: 35 (16/19) AZI: 33.3 ± 7.3
C: 32.6 ± 5.4
Parallel, Double Blind, Placebo Controlled AZI: Post-therapy
End of S/RSD in 3–5 times within 14 days.
C: S/RSD in 3–5 times within 14 days
Qu S/RSD (3–5 sessions) AZI: 500 g × 3 days
C: Placebo ×  3 days
1, 3, 6, 12 months from baseline 1st, 3rd, 6th, 12th week
  1. AZI Test group: Azithromycin + S/ RSD Group. C Control Group; SRSD alone, FMD Full mouth debridement, PMD Partial Mouth S/RSD,
  2. (studies are ordered by year of publication)